Tülay AYNA KILIÇASLAN, Hayriye ÇİFTÇİ ŞENTÜRK, Yaşar ÇALIŞKAN, Aydın TÜRKMEN, Mehmet GÜRTEKİN

Long-term effects of antibodies against human leukocyte antigens detected by flow cytometry in the first year after renal transplantation

Objective:In this study, we aimed to investigate the incidence, dynamics and profiles of human leukocyte antigen (HLA)-directed antibodies developedafter transplantation and their impact on graft rejection and outcome in kidney recipients. Study Design:Prospective follow-up study. Material and Methods:A total of 56 kidney recipients were monitored at 1 st , 6 thand 12 thmonths for the development of anti-HLA antibodies using beadbased flow-cytometry assays (Flow PRA tests).Results:In 21 (37.5%) patients, panel reactive antibodies (PRA) was positive after transplantation, however, in 35 (62.5%) patients PRA was found nega - tive. Twelve (57.1%) patients with post-transplantation HLA-reactive antibodies [PRA (+)] and 8 (22.9%) patients with no detectable alloantibodies [PRA(-)] were developed allograft rejection (p=0.010). In the PRA positive patient group the rates of early period infection and delayed graft function (DGF)were higher than the PRA negative patient group. Serum creatinine levels of PRA positive group at 6. and 12. months after transplantation were signifi - cantly higher than the PRA negative group (p=0.015 and p=0.048, respectively). The rejection rates of patients who had class I and II HLA antibodieswere significantly higher than the patients who had either class I or II HLA antibodies (p=0.011). Acute rejection rates were significantly higher in patientswho had class I and II HLA antibodies at the first month (p=0.007).Conclusion:Higher occurrence of rejection episodes in PRA positive group may show the importance of anti-HLA antibody monitoring using Flow-PRAafter renal transplantation as a prognostic marker in terms of graft survival

PDF

___

1.Mihaylova A, Baltadjieva D, Boneva P, Ivanova M, Penkova K, Ma rinova D, et al. Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays--single-center experience. Hum Immunol 2006;67:787-94. [CrossRef]
2.Panigrahi A, Gupta N, Siddiqui JA, Margoob A, Bhowmik D, Guleria S, et al. Post- transplant development of MICA and antiHLA anti bodies is associated with acute rejection episodes and renal allograft loss. Hum Immunol 2007;68:362-7. [CrossRef]
3.Van der Mast BJ, van Besouw NM, Witvliet MD, de Kuiper P, Smak Gregoor P, van Gelder T, et al. Formation of donor- specific human leukocyte antigen antibodies after kidney transplantation:correlation with acute rejection and tapering of immunosuppression. Transplantation 2003;75:871-7. [CrossRef]
4.Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies devel oped in the first year posttransplant are predictive of chronic rejec tion and renal graft loss. Transplantation 2009;88:568-74. [CrossRef]
5.Cardarelli F, Saidman S, Theruvath T, Tolkoff-Rubin N, Cosimi AB, Pascual M. The problem of late allograft loss in kidney transplan tation. Minerva Urol Nefrol 2003;55:1-11.
6.Saidman S. Significance of anti-HLA and donor-specific antibodies in long-term renal graft survival. Transplant Proc 2007;39:744-6. [CrossRef]
7.McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies af ter solid organ transplantation. Transplantation 2000;69:319-26. [CrossRef]
8.Fernández-Fresnedo G, Pastor JM, López-Hoyos M, Ruiz JC, Zu bimendi JA, Gonzalez-Cotorruelo J, et al. Relationship of donor- specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. Nephrol Dial Transplant 2003;18:990-5. [CrossRef]
9.Terasaki PI, Cai J. Humoral theory of transplantation:further evi dence. Curr Opin Immunol 2005;17:541-5. [CrossRef]
10.Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003;3:665-73. [CrossRef
11.Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection:from association to causation. Transplantation 2008;86:377-83. [CrossRef]
12.Stastny P, Ring S, Lu C, Arenas J, Han M, Lavingia B. Role of i- munoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum Immunol 2009;70:600-4. [CrossRef]
13.Lawson C, Holder AL, Stanford RE, Smith J, Rose ML. Anti-inter cellular adhesion molecule-1 antibodies in sera of heart trans plant recipients:a role in endothelial cell activation. Transplanta tion 2005;80:264-71. [CrossRef]
14.Everly MJ, Terasaki PI. Monitoring and treating posttransplant hu man leukocyte antigen antibodies. Hum Immunol 2009;70:655-9. [CrossRef]
15.Piazza A, Poggi E, Borrelli L, Servetti S, Monaco PI, Buonomo O, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation:posttransplant analysis using flow cytometric techniques. Transplantation 2001;71:1106-12. [CrossRef]
16.Costa AN, Scolari MP, Iannelli S, Buscaroli A, DArcangelo GL, Brando B, et al. The presence of posttransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent as say correlates with specific rejection pathologies. Transplantation 1997;63:167-9. [CrossRef]
17.Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964;204:998-1000. [CrossRef]
18.Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in two hours:An al ternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-35. [CrossRef]
19.Cardarelli F, Pascual M, Tolkoff-Rubin N, Delmonico FL, Wong W, Schoenfeld DA, et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplanta tion. Transpl Int 2005;18:532-40. [CrossRef]
20.Abe M, Kawai T, Futatsuyama K, Tanabe K, Fuchinoue S, Te raoka S, et al. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation. Transplantation 1997;63:1616-9. [CrossRef]
21.Neylan J, de Smet W, Stijlemans B, Brinker K, Gonwa T, Moran J, et al. Detection of clinically relevant antibodies pretransplant and post transplant with PRA-STAT. Transplant Proc 1997;29:330-2. [CrossRef]
22.Martin S, Dyer PA, Mallick NP, Gokal R, Harris R, Johnson RW. Posttransplant antidonor lymphocytotoxic antibody produc tion in relation to graft outcome. Transplantation 1987;44:50-3. [CrossRef]
23.Deka R, Panigrahi A, Aggarwal SK, Guleria S, Dash SC, Mehta SN, et al. Influence of pretransplant panel reactive antibod ies on the posttransplant sensitization status. Transplant Proc 2002;34:3082-3. [CrossRef]
24.Fritsche L, Hoerstrup J, Budde K, Reinke P, Neumayer H, Frei U, et al. Accurate prediction of kidney allograft outcome based on creatinine course in the first 6 months posttransplant.Transplant Proc 2005;37:731-3. [CrossRef]
25.Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002;73:1269-73. [CrossRef]
26.Patel R, Terasaki PI. Significance of the crossmatch test in kidney transplantation. N Engl J Med 1968;280:735. [CrossRef
27.Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, et al. All chronic rejection failures of kidney transplants were pre ceded by the development of HLA antibodies.Transplantation 2002;74:1192-4. [CrossRef]
28.Utzig MJ, Blümke M, Wolff-Vorbeck F, Lang H, Kirste G. Flow cy tometry crossmatch. Transplantation 1997;63:551-4. [CrossRef]
29.Smith RN, Kawai T, Boskovic S, Nadazdin O, Sachs DH, Cosimi AB, et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cyno molgus monkeys. Am J Transplant 2008;8:1662-72. [CrossRef]
30.Suciu-Foca N, Reed E, DAgati VD, Ho E, Cohen DJ, Benvenisty AI, et al. Soluble HLA antigens, anti-HLA antibodies, and antiid iotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991;51:593-601. [CrossRef]
31.Schönemann C, Groth J, Leverenz S, May G. HLA class I and class II antibodies:monitoring before and after kidney transplantation and their clinical relevance. Transplantation 1998;65:1519-23. [CrossRef]
32.Müller-Steinhardt M, Fricke L, Kirchner H, Hoyer J, Klüter H. Monitoring of anti-HLA class I and II antibodies by flow cytom etry in patients after first cadaveric kidney transplantation. Clin Transplant 2000;14:85-9. [CrossRef]